Expand ATAI Menu
ATAI MENU

ATAI Latest Press Releases

-- April 8, 2026 --

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs Globe Newswire 6:00 AM

-- March 24, 2026 --

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst Globe Newswire 6:00 AM

-- March 17, 2026 --

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation Globe Newswire 6:00 AM

-- March 10, 2026 --

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day Globe Newswire 6:00 AM

-- March 6, 2026 --

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Globe Newswire 7:00 AM

-- March 3, 2026 --

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression Globe Newswire 7:00 AM

-- February 26, 2026 --

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder Globe Newswire 7:00 AM

-- February 20, 2026 --

AtaiBeckley To Host Virtual Investor Day on March 6, 2026 Globe Newswire 7:00 AM

-- February 19, 2026 --

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer Globe Newswire 7:00 AM

-- February 17, 2026 --

AtaiBeckley To Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- January 16, 2026 --

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation Globe Newswire 7:00 AM

-- January 8, 2026 --

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 30, 2025 --

AtaiBeckley Completes Redomiciliation to the United States Globe Newswire 7:13 PM

-- December 23, 2025 --

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) Globe Newswire 7:00 AM

-- December 11, 2025 --

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio Globe Newswire 7:00 AM

-- November 19, 2025 --

Enhanced Fortifies Executive Leadership Team & Board of Directors PRNewswire 7:33 PM

-- November 13, 2025 --

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London Globe Newswire 9:00 AM

-- November 12, 2025 --

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Globe Newswire 7:00 AM

-- November 10, 2025 --

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes